Reviving old antibiotics

Author:

Theuretzbacher Ursula1,Van Bambeke Françoise2,Cantón Rafael3,Giske Christian G.45,Mouton Johan W.67,Nation Roger L.8,Paul Mical9,Turnidge John D.10,Kahlmeter Gunnar1112

Affiliation:

1. 1  Center for Anti-Infective Agents, Vienna, Austria

2. 2  Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium

3. 3  Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Biomédica (IRYCIS), Madrid, Spain

4. 4  Clinical Microbiology, L2:02, Karolinska University Hospital, Solna, Stockholm, Sweden

5. 5  Department of Laboratory Medicine (LABMED), Division of Clinical Microbiology, Karolinska Institutet, Huddinge, Sweden

6. 6  Department of Medical Microbiology and Infectious Diseases Erasmus MC, Rotterdam, The Netherlands

7. 7  Department of Medical Microbiology, Radboudumc Radboud University, Nijmegen, The Netherlands

8. 8  Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia

9. 9  Division of Infectious Diseases, Rambam Health Care Campus and Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

10. 10  School of Biological Sciences, University of Adelaide, Adelaide, South Australia, Australia

11. 11  Department of Clinical Microbiology, Central Hospital, Växjö, Sweden

12. 12  Department of Medical Sciences, Division of Clinical Bacteriology, Uppsala University, Uppsala, Sweden

Abstract

Abstract In the face of increasing antimicrobial resistance and the paucity of new antimicrobial agents it has become clear that new antimicrobial strategies are urgently needed. One of these is to revisit old antibiotics to ensure that they are used correctly and to their full potential, as well as to determine whether one or several of them can help alleviate the pressure on more recent agents. Strategies are urgently needed to ‘re-develop’ these drugs using modern standards, integrating new knowledge into regulatory frameworks and communicating the knowledge from the research bench to the bedside. Without a systematic approach to re-developing these old drugs and rigorously testing them according to today's standards, there is a significant risk of doing harm to patients and further increasing multidrug resistance. This paper describes factors to be considered and outlines steps and actions needed to re-develop old antibiotics so that they can be used effectively for the treatment of infections.

Funder

EU 7th Framework Program

Maître de Recherches of the Belgian Fonds de la Recherche Scientifique

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3